nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—kidney cancer—sarcoma	0.336	1	CtDrD
Pazopanib—FLT1—sarcoma	0.0953	0.26	CbGaD
Pazopanib—PDGFRB—sarcoma	0.0788	0.215	CbGaD
Pazopanib—PDGFRA—sarcoma	0.0768	0.209	CbGaD
Pazopanib—KDR—sarcoma	0.0597	0.163	CbGaD
Pazopanib—KIT—sarcoma	0.0564	0.154	CbGaD
Pazopanib—UGT1A1—Etoposide—sarcoma	0.0145	0.131	CbGbCtD
Pazopanib—ABCG2—Dactinomycin—sarcoma	0.0142	0.127	CbGbCtD
Pazopanib—ABCG2—Mitoxantrone—sarcoma	0.0127	0.114	CbGbCtD
Pazopanib—ABCG2—Vincristine—sarcoma	0.00872	0.0784	CbGbCtD
Pazopanib—ABCG2—Etoposide—sarcoma	0.00799	0.0718	CbGbCtD
Pazopanib—CYP1A2—Dacarbazine—sarcoma	0.00674	0.0605	CbGbCtD
Pazopanib—CYP3A4—Thiotepa—sarcoma	0.00637	0.0572	CbGbCtD
Pazopanib—ABCG2—Doxorubicin—sarcoma	0.00545	0.049	CbGbCtD
Pazopanib—ABCB1—Dactinomycin—sarcoma	0.00511	0.0459	CbGbCtD
Pazopanib—ABCB1—Mitoxantrone—sarcoma	0.00457	0.0411	CbGbCtD
Pazopanib—CYP2C8—Etoposide—sarcoma	0.00426	0.0383	CbGbCtD
Pazopanib—CYP1A2—Etoposide—sarcoma	0.0033	0.0296	CbGbCtD
Pazopanib—ABCB1—Vincristine—sarcoma	0.00315	0.0283	CbGbCtD
Pazopanib—ABCB1—Etoposide—sarcoma	0.00288	0.0259	CbGbCtD
Pazopanib—CYP3A4—Mitoxantrone—sarcoma	0.00274	0.0246	CbGbCtD
Pazopanib—ABCB1—Doxorubicin—sarcoma	0.00197	0.0177	CbGbCtD
Pazopanib—CYP3A4—Vincristine—sarcoma	0.00188	0.0169	CbGbCtD
Pazopanib—CYP2D6—Doxorubicin—sarcoma	0.00185	0.0166	CbGbCtD
Pazopanib—CYP3A4—Etoposide—sarcoma	0.00173	0.0155	CbGbCtD
Pazopanib—CYP3A4—Doxorubicin—sarcoma	0.00118	0.0106	CbGbCtD
Pazopanib—PLK4—Teniposide—Etoposide—sarcoma	0.000401	0.332	CbGdCrCtD
Pazopanib—PLK4—Doxorubicin—Epirubicin—sarcoma	0.000209	0.173	CbGdCrCtD
Pazopanib—PLK4—Idarubicin—Epirubicin—sarcoma	0.000209	0.173	CbGdCrCtD
Pazopanib—PLK4—Epirubicin—Doxorubicin—sarcoma	0.000194	0.16	CbGdCrCtD
Pazopanib—PLK4—Idarubicin—Doxorubicin—sarcoma	0.000194	0.16	CbGdCrCtD
Pazopanib—AURKC—tendon—sarcoma	0.000185	0.00347	CbGeAlD
Pazopanib—FGF1—embryo—sarcoma	0.000184	0.00346	CbGeAlD
Pazopanib—SH2B3—bone marrow—sarcoma	0.000182	0.00341	CbGeAlD
Pazopanib—ITK—testis—sarcoma	0.000181	0.00341	CbGeAlD
Pazopanib—RIOK2—cardiac atrium—sarcoma	0.00018	0.00338	CbGeAlD
Pazopanib—PLK4—lymphoid tissue—sarcoma	0.00018	0.00338	CbGeAlD
Pazopanib—BMPR1B—uterus—sarcoma	0.000177	0.00333	CbGeAlD
Pazopanib—KIT—mammary gland—sarcoma	0.000177	0.00333	CbGeAlD
Pazopanib—SLCO1B1—mammary gland—sarcoma	0.000176	0.0033	CbGeAlD
Pazopanib—MAP3K2—hematopoietic system—sarcoma	0.000174	0.00328	CbGeAlD
Pazopanib—FGFR2—embryo—sarcoma	0.000174	0.00327	CbGeAlD
Pazopanib—PDGFRB—mammary gland—sarcoma	0.000173	0.00325	CbGeAlD
Pazopanib—STK16—lymphoid tissue—sarcoma	0.00017	0.00319	CbGeAlD
Pazopanib—MAP3K2—connective tissue—sarcoma	0.000168	0.00316	CbGeAlD
Pazopanib—LYN—lymphoid tissue—sarcoma	0.000168	0.00315	CbGeAlD
Pazopanib—FLT1—myometrium—sarcoma	0.000168	0.00315	CbGeAlD
Pazopanib—EPHB6—myometrium—sarcoma	0.000166	0.00311	CbGeAlD
Pazopanib—TAOK1—testis—sarcoma	0.000165	0.0031	CbGeAlD
Pazopanib—FGF1—hematopoietic system—sarcoma	0.000164	0.00309	CbGeAlD
Pazopanib—PLK4—bone marrow—sarcoma	0.000164	0.00307	CbGeAlD
Pazopanib—FLT1—embryo—sarcoma	0.000161	0.00303	CbGeAlD
Pazopanib—STK16—tendon—sarcoma	0.000159	0.003	CbGeAlD
Pazopanib—PI4KB—cardiac atrium—sarcoma	0.000159	0.00299	CbGeAlD
Pazopanib—MAP3K9—lymph node—sarcoma	0.000159	0.00299	CbGeAlD
Pazopanib—STK10—myometrium—sarcoma	0.000159	0.00298	CbGeAlD
Pazopanib—PI4KB—uterus—sarcoma	0.000158	0.00298	CbGeAlD
Pazopanib—FGF1—connective tissue—sarcoma	0.000158	0.00297	CbGeAlD
Pazopanib—TAOK3—myometrium—sarcoma	0.000158	0.00297	CbGeAlD
Pazopanib—RIOK2—tendon—sarcoma	0.000157	0.00295	CbGeAlD
Pazopanib—TAOK1—liver—sarcoma	0.000156	0.00293	CbGeAlD
Pazopanib—LIMK2—uterus—sarcoma	0.000156	0.00292	CbGeAlD
Pazopanib—SH2B3—testis—sarcoma	0.000155	0.00292	CbGeAlD
Pazopanib—FGFR2—hematopoietic system—sarcoma	0.000155	0.00292	CbGeAlD
Pazopanib—AURKC—testis—sarcoma	0.000153	0.00287	CbGeAlD
Pazopanib—RIOK2—bone marrow—sarcoma	0.000152	0.00286	CbGeAlD
Pazopanib—FLT1—seminal vesicle—sarcoma	0.000151	0.00285	CbGeAlD
Pazopanib—PDGFRA—embryo—sarcoma	0.000151	0.00284	CbGeAlD
Pazopanib—EPHB6—seminal vesicle—sarcoma	0.00015	0.00281	CbGeAlD
Pazopanib—FGFR2—connective tissue—sarcoma	0.000149	0.00281	CbGeAlD
Pazopanib—SH2B3—liver—sarcoma	0.000147	0.00276	CbGeAlD
Pazopanib—LIMK2—lymphoid tissue—sarcoma	0.000145	0.00273	CbGeAlD
Pazopanib—FGF1—smooth muscle tissue—sarcoma	0.000145	0.00272	CbGeAlD
Pazopanib—FLT1—hematopoietic system—sarcoma	0.000144	0.0027	CbGeAlD
Pazopanib—FGF1—skin of body—sarcoma	0.000143	0.00269	CbGeAlD
Pazopanib—TAOK3—seminal vesicle—sarcoma	0.000143	0.00268	CbGeAlD
Pazopanib—KDR—myometrium—sarcoma	0.000142	0.00266	CbGeAlD
Pazopanib—MAP2K5—myometrium—sarcoma	0.000142	0.00266	CbGeAlD
Pazopanib—STK36—tendon—sarcoma	0.000141	0.00265	CbGeAlD
Pazopanib—PLK4—testis—sarcoma	0.00014	0.00263	CbGeAlD
Pazopanib—PIP4K2C—cardiac atrium—sarcoma	0.00014	0.00263	CbGeAlD
Pazopanib—PI4KB—tendon—sarcoma	0.000139	0.00261	CbGeAlD
Pazopanib—FGFR1—cardiac atrium—sarcoma	0.000139	0.00261	CbGeAlD
Pazopanib—FLT1—connective tissue—sarcoma	0.000139	0.0026	CbGeAlD
Pazopanib—CSF1R—myometrium—sarcoma	0.000138	0.0026	CbGeAlD
Pazopanib—FGFR1—uterus—sarcoma	0.000138	0.00259	CbGeAlD
Pazopanib—FGFR2—smooth muscle tissue—sarcoma	0.000137	0.00257	CbGeAlD
Pazopanib—KDR—embryo—sarcoma	0.000136	0.00256	CbGeAlD
Pazopanib—STK10—hematopoietic system—sarcoma	0.000136	0.00256	CbGeAlD
Pazopanib—TAOK3—hematopoietic system—sarcoma	0.000136	0.00255	CbGeAlD
Pazopanib—FGFR2—skin of body—sarcoma	0.000135	0.00254	CbGeAlD
Pazopanib—PDGFRA—hematopoietic system—sarcoma	0.000135	0.00253	CbGeAlD
Pazopanib—PI4KB—bone marrow—sarcoma	0.000134	0.00253	CbGeAlD
Pazopanib—CSF1R—embryo—sarcoma	0.000133	0.0025	CbGeAlD
Pazopanib—STK16—testis—sarcoma	0.000132	0.00248	CbGeAlD
Pazopanib—MAP3K2—uterus—sarcoma	0.000132	0.00248	CbGeAlD
Pazopanib—ITK—lymph node—sarcoma	0.000131	0.00247	CbGeAlD
Pazopanib—TAOK3—connective tissue—sarcoma	0.000131	0.00246	CbGeAlD
Pazopanib—FLT4—lymphoid tissue—sarcoma	0.00013	0.00245	CbGeAlD
Pazopanib—FGFR3—testis—sarcoma	0.00013	0.00244	CbGeAlD
Pazopanib—RIOK2—testis—sarcoma	0.00013	0.00244	CbGeAlD
Pazopanib—PDGFRA—connective tissue—sarcoma	0.00013	0.00244	CbGeAlD
Pazopanib—BMPR1B—testis—sarcoma	0.000129	0.00242	CbGeAlD
Pazopanib—MAP3K19—testis—sarcoma	0.000129	0.00242	CbGeAlD
Pazopanib—UGT1A1—hematopoietic system—sarcoma	0.000129	0.00242	CbGeAlD
Pazopanib—MAP2K5—seminal vesicle—sarcoma	0.000128	0.00241	CbGeAlD
Pazopanib—KDR—seminal vesicle—sarcoma	0.000128	0.00241	CbGeAlD
Pazopanib—FLT1—smooth muscle tissue—sarcoma	0.000127	0.00238	CbGeAlD
Pazopanib—KIT—myometrium—sarcoma	0.000126	0.00236	CbGeAlD
Pazopanib—CSF1R—seminal vesicle—sarcoma	0.000125	0.00235	CbGeAlD
Pazopanib—FGF1—cardiac atrium—sarcoma	0.000125	0.00235	CbGeAlD
Pazopanib—STK16—liver—sarcoma	0.000125	0.00235	CbGeAlD
Pazopanib—EPHB6—skin of body—sarcoma	0.000124	0.00232	CbGeAlD
Pazopanib—LYN—liver—sarcoma	0.000123	0.00232	CbGeAlD
Pazopanib—LCK—uterus—sarcoma	0.000123	0.00232	CbGeAlD
Pazopanib—FGFR3—liver—sarcoma	0.000123	0.00231	CbGeAlD
Pazopanib—RIOK2—liver—sarcoma	0.000123	0.00231	CbGeAlD
Pazopanib—MAP3K2—lymphoid tissue—sarcoma	0.000123	0.00231	CbGeAlD
Pazopanib—PDGFRB—myometrium—sarcoma	0.000123	0.0023	CbGeAlD
Pazopanib—PIP4K2C—tendon—sarcoma	0.000122	0.00229	CbGeAlD
Pazopanib—KDR—hematopoietic system—sarcoma	0.000122	0.00229	CbGeAlD
Pazopanib—FGFR1—tendon—sarcoma	0.000121	0.00227	CbGeAlD
Pazopanib—KIT—embryo—sarcoma	0.000121	0.00227	CbGeAlD
Pazopanib—TAOK1—lymph node—sarcoma	0.00012	0.00225	CbGeAlD
Pazopanib—PDGFRA—smooth muscle tissue—sarcoma	0.000119	0.00223	CbGeAlD
Pazopanib—CSF1R—hematopoietic system—sarcoma	0.000119	0.00223	CbGeAlD
Pazopanib—FLT4—bone marrow—sarcoma	0.000119	0.00223	CbGeAlD
Pazopanib—PIP4K2C—bone marrow—sarcoma	0.000118	0.00222	CbGeAlD
Pazopanib—PDGFRB—embryo—sarcoma	0.000118	0.00222	CbGeAlD
Pazopanib—FGFR2—uterus—sarcoma	0.000117	0.0022	CbGeAlD
Pazopanib—KDR—connective tissue—sarcoma	0.000117	0.0022	CbGeAlD
Pazopanib—STK36—testis—sarcoma	0.000117	0.00219	CbGeAlD
Pazopanib—FGF1—lymphoid tissue—sarcoma	0.000116	0.00218	CbGeAlD
Pazopanib—PI4KB—testis—sarcoma	0.000115	0.00216	CbGeAlD
Pazopanib—CSF1R—connective tissue—sarcoma	0.000114	0.00215	CbGeAlD
Pazopanib—KIT—seminal vesicle—sarcoma	0.000113	0.00213	CbGeAlD
Pazopanib—LIMK2—testis—sarcoma	0.000113	0.00212	CbGeAlD
Pazopanib—SH2B3—lymph node—sarcoma	0.000113	0.00212	CbGeAlD
Pazopanib—MAP3K2—bone marrow—sarcoma	0.000112	0.0021	CbGeAlD
Pazopanib—AURKC—lymph node—sarcoma	0.000111	0.00208	CbGeAlD
Pazopanib—PDGFRB—seminal vesicle—sarcoma	0.000111	0.00208	CbGeAlD
Pazopanib—STK36—liver—sarcoma	0.00011	0.00207	CbGeAlD
Pazopanib—FLT1—cardiac atrium—sarcoma	0.000109	0.00205	CbGeAlD
Pazopanib—FLT1—uterus—sarcoma	0.000109	0.00204	CbGeAlD
Pazopanib—PI4KB—liver—sarcoma	0.000109	0.00204	CbGeAlD
Pazopanib—EPHB6—cardiac atrium—sarcoma	0.000108	0.00203	CbGeAlD
Pazopanib—KIT—hematopoietic system—sarcoma	0.000108	0.00203	CbGeAlD
Pazopanib—KDR—smooth muscle tissue—sarcoma	0.000107	0.00201	CbGeAlD
Pazopanib—SLCO1B1—hematopoietic system—sarcoma	0.000107	0.00201	CbGeAlD
Pazopanib—LIMK2—liver—sarcoma	0.000107	0.00201	CbGeAlD
Pazopanib—PDGFRB—hematopoietic system—sarcoma	0.000105	0.00198	CbGeAlD
Pazopanib—LCK—bone marrow—sarcoma	0.000105	0.00197	CbGeAlD
Pazopanib—CSF1R—smooth muscle tissue—sarcoma	0.000105	0.00197	CbGeAlD
Pazopanib—KIT—connective tissue—sarcoma	0.000104	0.00195	CbGeAlD
Pazopanib—CSF1R—skin of body—sarcoma	0.000103	0.00194	CbGeAlD
Pazopanib—TAOK3—cardiac atrium—sarcoma	0.000103	0.00194	CbGeAlD
Pazopanib—STK10—uterus—sarcoma	0.000103	0.00193	CbGeAlD
Pazopanib—TAOK3—uterus—sarcoma	0.000102	0.00193	CbGeAlD
Pazopanib—PDGFRA—uterus—sarcoma	0.000102	0.00191	CbGeAlD
Pazopanib—FLT4—testis—sarcoma	0.000101	0.00191	CbGeAlD
Pazopanib—PDGFRB—connective tissue—sarcoma	0.000101	0.00191	CbGeAlD
Pazopanib—PLK4—lymph node—sarcoma	0.000101	0.0019	CbGeAlD
Pazopanib—FLT1—lymphoid tissue—sarcoma	0.000101	0.0019	CbGeAlD
Pazopanib—PIP4K2C—testis—sarcoma	0.000101	0.0019	CbGeAlD
Pazopanib—FGFR1—testis—sarcoma	0.0001	0.00188	CbGeAlD
Pazopanib—CYP2C8—mammary gland—sarcoma	9.99e-05	0.00188	CbGeAlD
Pazopanib—STK10—lymphoid tissue—sarcoma	9.59e-05	0.0018	CbGeAlD
Pazopanib—FLT4—liver—sarcoma	9.59e-05	0.0018	CbGeAlD
Pazopanib—STK16—lymph node—sarcoma	9.57e-05	0.0018	CbGeAlD
Pazopanib—MAP3K2—testis—sarcoma	9.56e-05	0.0018	CbGeAlD
Pazopanib—TAOK3—lymphoid tissue—sarcoma	9.55e-05	0.0018	CbGeAlD
Pazopanib—PIP4K2C—liver—sarcoma	9.54e-05	0.00179	CbGeAlD
Pazopanib—FLT1—tendon—sarcoma	9.52e-05	0.00179	CbGeAlD
Pazopanib—KIT—smooth muscle tissue—sarcoma	9.49e-05	0.00178	CbGeAlD
Pazopanib—PDGFRA—lymphoid tissue—sarcoma	9.49e-05	0.00178	CbGeAlD
Pazopanib—FGFR1—liver—sarcoma	9.46e-05	0.00178	CbGeAlD
Pazopanib—RIOK2—lymph node—sarcoma	9.42e-05	0.00177	CbGeAlD
Pazopanib—EPHB6—tendon—sarcoma	9.41e-05	0.00177	CbGeAlD
Pazopanib—KIT—skin of body—sarcoma	9.37e-05	0.00176	CbGeAlD
Pazopanib—BMPR1B—lymph node—sarcoma	9.33e-05	0.00175	CbGeAlD
Pazopanib—PDGFRB—smooth muscle tissue—sarcoma	9.27e-05	0.00174	CbGeAlD
Pazopanib—KDR—cardiac atrium—sarcoma	9.24e-05	0.00174	CbGeAlD
Pazopanib—MAP2K5—cardiac atrium—sarcoma	9.24e-05	0.00174	CbGeAlD
Pazopanib—KDR—uterus—sarcoma	9.19e-05	0.00173	CbGeAlD
Pazopanib—PDGFRB—skin of body—sarcoma	9.15e-05	0.00172	CbGeAlD
Pazopanib—MAP3K2—liver—sarcoma	9.04e-05	0.0017	CbGeAlD
Pazopanib—STK10—tendon—sarcoma	9.01e-05	0.00169	CbGeAlD
Pazopanib—CSF1R—cardiac atrium—sarcoma	9.01e-05	0.00169	CbGeAlD
Pazopanib—FGF1—testis—sarcoma	9.01e-05	0.00169	CbGeAlD
Pazopanib—TAOK3—tendon—sarcoma	8.98e-05	0.00169	CbGeAlD
Pazopanib—CSF1R—uterus—sarcoma	8.97e-05	0.00169	CbGeAlD
Pazopanib—LCK—testis—sarcoma	8.95e-05	0.00168	CbGeAlD
Pazopanib—PDGFRA—tendon—sarcoma	8.92e-05	0.00168	CbGeAlD
Pazopanib—STK10—bone marrow—sarcoma	8.73e-05	0.00164	CbGeAlD
Pazopanib—TAOK3—bone marrow—sarcoma	8.7e-05	0.00163	CbGeAlD
Pazopanib—KDR—lymphoid tissue—sarcoma	8.56e-05	0.00161	CbGeAlD
Pazopanib—FGF1—liver—sarcoma	8.52e-05	0.0016	CbGeAlD
Pazopanib—FGFR2—testis—sarcoma	8.51e-05	0.0016	CbGeAlD
Pazopanib—LCK—liver—sarcoma	8.46e-05	0.00159	CbGeAlD
Pazopanib—STK36—lymph node—sarcoma	8.46e-05	0.00159	CbGeAlD
Pazopanib—CSF1R—lymphoid tissue—sarcoma	8.36e-05	0.00157	CbGeAlD
Pazopanib—PI4KB—lymph node—sarcoma	8.33e-05	0.00157	CbGeAlD
Pazopanib—LIMK2—lymph node—sarcoma	8.18e-05	0.00154	CbGeAlD
Pazopanib—KIT—uterus—sarcoma	8.14e-05	0.00153	CbGeAlD
Pazopanib—MAP2K5—tendon—sarcoma	8.05e-05	0.00151	CbGeAlD
Pazopanib—KDR—tendon—sarcoma	8.05e-05	0.00151	CbGeAlD
Pazopanib—FGFR2—liver—sarcoma	8.04e-05	0.00151	CbGeAlD
Pazopanib—PDGFRB—cardiac atrium—sarcoma	7.99e-05	0.0015	CbGeAlD
Pazopanib—PDGFRB—uterus—sarcoma	7.95e-05	0.00149	CbGeAlD
Pazopanib—FLT1—testis—sarcoma	7.89e-05	0.00148	CbGeAlD
Pazopanib—CSF1R—tendon—sarcoma	7.86e-05	0.00148	CbGeAlD
Pazopanib—KDR—bone marrow—sarcoma	7.8e-05	0.00147	CbGeAlD
Pazopanib—EPHB6—testis—sarcoma	7.79e-05	0.00147	CbGeAlD
Pazopanib—CSF1R—bone marrow—sarcoma	7.61e-05	0.00143	CbGeAlD
Pazopanib—KIT—lymphoid tissue—sarcoma	7.59e-05	0.00143	CbGeAlD
Pazopanib—STK10—testis—sarcoma	7.46e-05	0.0014	CbGeAlD
Pazopanib—FLT1—liver—sarcoma	7.45e-05	0.0014	CbGeAlD
Pazopanib—TAOK3—testis—sarcoma	7.44e-05	0.0014	CbGeAlD
Pazopanib—PDGFRB—lymphoid tissue—sarcoma	7.41e-05	0.00139	CbGeAlD
Pazopanib—PDGFRA—testis—sarcoma	7.39e-05	0.00139	CbGeAlD
Pazopanib—FLT4—lymph node—sarcoma	7.35e-05	0.00138	CbGeAlD
Pazopanib—PIP4K2C—lymph node—sarcoma	7.31e-05	0.00137	CbGeAlD
Pazopanib—FGFR1—lymph node—sarcoma	7.25e-05	0.00136	CbGeAlD
Pazopanib—STK10—liver—sarcoma	7.06e-05	0.00133	CbGeAlD
Pazopanib—TAOK3—liver—sarcoma	7.03e-05	0.00132	CbGeAlD
Pazopanib—PDGFRA—liver—sarcoma	6.99e-05	0.00131	CbGeAlD
Pazopanib—PDGFRB—tendon—sarcoma	6.97e-05	0.00131	CbGeAlD
Pazopanib—MAP3K2—lymph node—sarcoma	6.93e-05	0.0013	CbGeAlD
Pazopanib—KIT—bone marrow—sarcoma	6.91e-05	0.0013	CbGeAlD
Pazopanib—ABCG2—myometrium—sarcoma	6.89e-05	0.0013	CbGeAlD
Pazopanib—PDGFRB—bone marrow—sarcoma	6.75e-05	0.00127	CbGeAlD
Pazopanib—KDR—testis—sarcoma	6.67e-05	0.00125	CbGeAlD
Pazopanib—MAP2K5—testis—sarcoma	6.67e-05	0.00125	CbGeAlD
Pazopanib—UGT1A1—liver—sarcoma	6.66e-05	0.00125	CbGeAlD
Pazopanib—FGF1—lymph node—sarcoma	6.53e-05	0.00123	CbGeAlD
Pazopanib—CSF1R—testis—sarcoma	6.51e-05	0.00122	CbGeAlD
Pazopanib—LCK—lymph node—sarcoma	6.49e-05	0.00122	CbGeAlD
Pazopanib—KDR—liver—sarcoma	6.3e-05	0.00118	CbGeAlD
Pazopanib—MAP2K5—liver—sarcoma	6.3e-05	0.00118	CbGeAlD
Pazopanib—ABCG2—seminal vesicle—sarcoma	6.23e-05	0.00117	CbGeAlD
Pazopanib—CSF1R—liver—sarcoma	6.15e-05	0.00116	CbGeAlD
Pazopanib—CYP2C8—hematopoietic system—sarcoma	6.09e-05	0.00114	CbGeAlD
Pazopanib—KIT—testis—sarcoma	5.91e-05	0.00111	CbGeAlD
Pazopanib—PDGFRB—testis—sarcoma	5.77e-05	0.00108	CbGeAlD
Pazopanib—FLT1—lymph node—sarcoma	5.72e-05	0.00107	CbGeAlD
Pazopanib—CYP1A2—hematopoietic system—sarcoma	5.69e-05	0.00107	CbGeAlD
Pazopanib—Paraesthesia—Vincristine—sarcoma	5.68e-05	0.00114	CcSEcCtD
Pazopanib—EPHB6—lymph node—sarcoma	5.65e-05	0.00106	CbGeAlD
Pazopanib—Face oedema—Epirubicin—sarcoma	5.64e-05	0.00113	CcSEcCtD
Pazopanib—Abdominal pain—Thiotepa—sarcoma	5.64e-05	0.00113	CcSEcCtD
Pazopanib—Leukopenia—Etoposide—sarcoma	5.62e-05	0.00112	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Mitoxantrone—sarcoma	5.61e-05	0.00112	CcSEcCtD
Pazopanib—Abdominal pain—Dactinomycin—sarcoma	5.59e-05	0.00112	CcSEcCtD
Pazopanib—KIT—liver—sarcoma	5.58e-05	0.00105	CbGeAlD
Pazopanib—SLCO1B1—liver—sarcoma	5.55e-05	0.00104	CbGeAlD
Pazopanib—Cardiac failure—Doxorubicin—sarcoma	5.54e-05	0.00111	CcSEcCtD
Pazopanib—Paraesthesia—Mitoxantrone—sarcoma	5.53e-05	0.00111	CcSEcCtD
Pazopanib—Loss of consciousness—Etoposide—sarcoma	5.52e-05	0.0011	CcSEcCtD
Pazopanib—Cerebrovascular accident—Doxorubicin—sarcoma	5.52e-05	0.0011	CcSEcCtD
Pazopanib—Lethargy—Doxorubicin—sarcoma	5.52e-05	0.0011	CcSEcCtD
Pazopanib—Decreased appetite—Vincristine—sarcoma	5.5e-05	0.0011	CcSEcCtD
Pazopanib—Dyspnoea—Mitoxantrone—sarcoma	5.49e-05	0.0011	CcSEcCtD
Pazopanib—Cough—Etoposide—sarcoma	5.48e-05	0.0011	CcSEcCtD
Pazopanib—Somnolence—Mitoxantrone—sarcoma	5.47e-05	0.0011	CcSEcCtD
Pazopanib—Blood creatinine increased—Epirubicin—sarcoma	5.47e-05	0.00109	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Vincristine—sarcoma	5.46e-05	0.00109	CcSEcCtD
Pazopanib—PDGFRB—liver—sarcoma	5.45e-05	0.00103	CbGeAlD
Pazopanib—Fatigue—Vincristine—sarcoma	5.45e-05	0.00109	CcSEcCtD
Pazopanib—Dehydration—Epirubicin—sarcoma	5.43e-05	0.00109	CcSEcCtD
Pazopanib—Hyponatraemia—Doxorubicin—sarcoma	5.43e-05	0.00109	CcSEcCtD
Pazopanib—Dyspepsia—Mitoxantrone—sarcoma	5.42e-05	0.00108	CcSEcCtD
Pazopanib—Hypertension—Etoposide—sarcoma	5.42e-05	0.00108	CcSEcCtD
Pazopanib—STK10—lymph node—sarcoma	5.41e-05	0.00102	CbGeAlD
Pazopanib—Pain—Vincristine—sarcoma	5.41e-05	0.00108	CcSEcCtD
Pazopanib—Gastrointestinal haemorrhage—Doxorubicin—sarcoma	5.4e-05	0.00108	CcSEcCtD
Pazopanib—Liver function test abnormal—Epirubicin—sarcoma	5.39e-05	0.00108	CcSEcCtD
Pazopanib—TAOK3—lymph node—sarcoma	5.39e-05	0.00101	CbGeAlD
Pazopanib—PDGFRA—lymph node—sarcoma	5.36e-05	0.00101	CbGeAlD
Pazopanib—Dry skin—Epirubicin—sarcoma	5.35e-05	0.00107	CcSEcCtD
Pazopanib—Decreased appetite—Mitoxantrone—sarcoma	5.35e-05	0.00107	CcSEcCtD
Pazopanib—Chest pain—Etoposide—sarcoma	5.34e-05	0.00107	CcSEcCtD
Pazopanib—Abdominal pain upper—Epirubicin—sarcoma	5.34e-05	0.00107	CcSEcCtD
Pazopanib—Fatigue—Mitoxantrone—sarcoma	5.31e-05	0.00106	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	5.31e-05	0.00106	CcSEcCtD
Pazopanib—Breast disorder—Epirubicin—sarcoma	5.28e-05	0.00106	CcSEcCtD
Pazopanib—Pain—Mitoxantrone—sarcoma	5.27e-05	0.00105	CcSEcCtD
Pazopanib—Aspartate aminotransferase increased—Epirubicin—sarcoma	5.26e-05	0.00105	CcSEcCtD
Pazopanib—Nasopharyngitis—Epirubicin—sarcoma	5.22e-05	0.00104	CcSEcCtD
Pazopanib—Face oedema—Doxorubicin—sarcoma	5.22e-05	0.00104	CcSEcCtD
Pazopanib—Gastrointestinal pain—Vincristine—sarcoma	5.17e-05	0.00103	CcSEcCtD
Pazopanib—Alanine aminotransferase increased—Epirubicin—sarcoma	5.15e-05	0.00103	CcSEcCtD
Pazopanib—Asthenia—Thiotepa—sarcoma	5.12e-05	0.00102	CcSEcCtD
Pazopanib—Infection—Etoposide—sarcoma	5.09e-05	0.00102	CcSEcCtD
Pazopanib—Abdominal distension—Epirubicin—sarcoma	5.08e-05	0.00102	CcSEcCtD
Pazopanib—Asthenia—Dactinomycin—sarcoma	5.08e-05	0.00102	CcSEcCtD
Pazopanib—Blood creatinine increased—Doxorubicin—sarcoma	5.06e-05	0.00101	CcSEcCtD
Pazopanib—Pruritus—Thiotepa—sarcoma	5.04e-05	0.00101	CcSEcCtD
Pazopanib—Gastrointestinal pain—Mitoxantrone—sarcoma	5.04e-05	0.00101	CcSEcCtD
Pazopanib—Dehydration—Doxorubicin—sarcoma	5.03e-05	0.00101	CcSEcCtD
Pazopanib—Thrombocytopenia—Etoposide—sarcoma	5.01e-05	0.001	CcSEcCtD
Pazopanib—Abdominal pain—Vincristine—sarcoma	5e-05	0.001	CcSEcCtD
Pazopanib—Liver function test abnormal—Doxorubicin—sarcoma	4.99e-05	0.000998	CcSEcCtD
Pazopanib—Skin disorder—Etoposide—sarcoma	4.97e-05	0.000995	CcSEcCtD
Pazopanib—Dry skin—Doxorubicin—sarcoma	4.95e-05	0.000991	CcSEcCtD
Pazopanib—Hyperhidrosis—Etoposide—sarcoma	4.95e-05	0.00099	CcSEcCtD
Pazopanib—Pancreatitis—Epirubicin—sarcoma	4.95e-05	0.00099	CcSEcCtD
Pazopanib—Abdominal pain upper—Doxorubicin—sarcoma	4.94e-05	0.000987	CcSEcCtD
Pazopanib—Breast disorder—Doxorubicin—sarcoma	4.88e-05	0.000977	CcSEcCtD
Pazopanib—Anorexia—Etoposide—sarcoma	4.88e-05	0.000977	CcSEcCtD
Pazopanib—Diarrhoea—Thiotepa—sarcoma	4.88e-05	0.000976	CcSEcCtD
Pazopanib—Abdominal pain—Mitoxantrone—sarcoma	4.87e-05	0.000974	CcSEcCtD
Pazopanib—Aspartate aminotransferase increased—Doxorubicin—sarcoma	4.87e-05	0.000974	CcSEcCtD
Pazopanib—Diarrhoea—Dactinomycin—sarcoma	4.84e-05	0.000969	CcSEcCtD
Pazopanib—Nasopharyngitis—Doxorubicin—sarcoma	4.83e-05	0.000967	CcSEcCtD
Pazopanib—MAP2K5—lymph node—sarcoma	4.83e-05	0.000908	CbGeAlD
Pazopanib—KDR—lymph node—sarcoma	4.83e-05	0.000908	CbGeAlD
Pazopanib—Alanine aminotransferase increased—Doxorubicin—sarcoma	4.77e-05	0.000954	CcSEcCtD
Pazopanib—Neutropenia—Epirubicin—sarcoma	4.72e-05	0.000944	CcSEcCtD
Pazopanib—CSF1R—lymph node—sarcoma	4.72e-05	0.000886	CbGeAlD
Pazopanib—Dizziness—Thiotepa—sarcoma	4.72e-05	0.000943	CcSEcCtD
Pazopanib—Abdominal distension—Doxorubicin—sarcoma	4.7e-05	0.000941	CcSEcCtD
Pazopanib—Photosensitivity reaction—Epirubicin—sarcoma	4.61e-05	0.000922	CcSEcCtD
Pazopanib—Paraesthesia—Etoposide—sarcoma	4.6e-05	0.00092	CcSEcCtD
Pazopanib—Pancreatitis—Doxorubicin—sarcoma	4.58e-05	0.000916	CcSEcCtD
Pazopanib—Weight decreased—Epirubicin—sarcoma	4.57e-05	0.000914	CcSEcCtD
Pazopanib—Dyspnoea—Etoposide—sarcoma	4.57e-05	0.000913	CcSEcCtD
Pazopanib—Somnolence—Etoposide—sarcoma	4.55e-05	0.000911	CcSEcCtD
Pazopanib—Asthenia—Vincristine—sarcoma	4.54e-05	0.000907	CcSEcCtD
Pazopanib—Vomiting—Thiotepa—sarcoma	4.53e-05	0.000907	CcSEcCtD
Pazopanib—Infestation NOS—Epirubicin—sarcoma	4.5e-05	0.0009	CcSEcCtD
Pazopanib—Infestation—Epirubicin—sarcoma	4.5e-05	0.0009	CcSEcCtD
Pazopanib—Vomiting—Dactinomycin—sarcoma	4.5e-05	0.0009	CcSEcCtD
Pazopanib—Rash—Thiotepa—sarcoma	4.5e-05	0.000899	CcSEcCtD
Pazopanib—Dermatitis—Thiotepa—sarcoma	4.49e-05	0.000898	CcSEcCtD
Pazopanib—ABCG2—uterus—sarcoma	4.47e-05	0.00084	CbGeAlD
Pazopanib—Headache—Thiotepa—sarcoma	4.47e-05	0.000894	CcSEcCtD
Pazopanib—Rash—Dactinomycin—sarcoma	4.46e-05	0.000893	CcSEcCtD
Pazopanib—Decreased appetite—Etoposide—sarcoma	4.45e-05	0.000891	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Etoposide—sarcoma	4.42e-05	0.000885	CcSEcCtD
Pazopanib—Asthenia—Mitoxantrone—sarcoma	4.42e-05	0.000884	CcSEcCtD
Pazopanib—Fatigue—Etoposide—sarcoma	4.42e-05	0.000883	CcSEcCtD
Pazopanib—Jaundice—Epirubicin—sarcoma	4.39e-05	0.000878	CcSEcCtD
Pazopanib—Stomatitis—Epirubicin—sarcoma	4.39e-05	0.000878	CcSEcCtD
Pazopanib—Pain—Etoposide—sarcoma	4.38e-05	0.000876	CcSEcCtD
Pazopanib—Neutropenia—Doxorubicin—sarcoma	4.37e-05	0.000874	CcSEcCtD
Pazopanib—Diarrhoea—Vincristine—sarcoma	4.33e-05	0.000865	CcSEcCtD
Pazopanib—Haematuria—Epirubicin—sarcoma	4.29e-05	0.000859	CcSEcCtD
Pazopanib—KIT—lymph node—sarcoma	4.28e-05	0.000805	CbGeAlD
Pazopanib—Photosensitivity reaction—Doxorubicin—sarcoma	4.26e-05	0.000853	CcSEcCtD
Pazopanib—Hepatobiliary disease—Epirubicin—sarcoma	4.26e-05	0.000852	CcSEcCtD
Pazopanib—Epistaxis—Epirubicin—sarcoma	4.25e-05	0.000849	CcSEcCtD
Pazopanib—Nausea—Thiotepa—sarcoma	4.24e-05	0.000847	CcSEcCtD
Pazopanib—Weight decreased—Doxorubicin—sarcoma	4.23e-05	0.000845	CcSEcCtD
Pazopanib—Diarrhoea—Mitoxantrone—sarcoma	4.21e-05	0.000843	CcSEcCtD
Pazopanib—Nausea—Dactinomycin—sarcoma	4.2e-05	0.000841	CcSEcCtD
Pazopanib—Gastrointestinal pain—Etoposide—sarcoma	4.19e-05	0.000838	CcSEcCtD
Pazopanib—PDGFRB—lymph node—sarcoma	4.18e-05	0.000786	CbGeAlD
Pazopanib—Dizziness—Vincristine—sarcoma	4.18e-05	0.000836	CcSEcCtD
Pazopanib—Infestation NOS—Doxorubicin—sarcoma	4.17e-05	0.000833	CcSEcCtD
Pazopanib—Infestation—Doxorubicin—sarcoma	4.17e-05	0.000833	CcSEcCtD
Pazopanib—CYP3A4—hematopoietic system—sarcoma	4.12e-05	0.000775	CbGeAlD
Pazopanib—Bradycardia—Epirubicin—sarcoma	4.11e-05	0.000823	CcSEcCtD
Pazopanib—Haemoglobin—Epirubicin—sarcoma	4.06e-05	0.000812	CcSEcCtD
Pazopanib—Stomatitis—Doxorubicin—sarcoma	4.06e-05	0.000812	CcSEcCtD
Pazopanib—Jaundice—Doxorubicin—sarcoma	4.06e-05	0.000812	CcSEcCtD
Pazopanib—CYP2D6—hematopoietic system—sarcoma	4.06e-05	0.000762	CbGeAlD
Pazopanib—Abdominal pain—Etoposide—sarcoma	4.05e-05	0.00081	CcSEcCtD
Pazopanib—Haemorrhage—Epirubicin—sarcoma	4.04e-05	0.000808	CcSEcCtD
Pazopanib—Hypoaesthesia—Epirubicin—sarcoma	4.02e-05	0.000804	CcSEcCtD
Pazopanib—Vomiting—Vincristine—sarcoma	4.02e-05	0.000804	CcSEcCtD
Pazopanib—Urinary tract disorder—Epirubicin—sarcoma	3.99e-05	0.000798	CcSEcCtD
Pazopanib—Rash—Vincristine—sarcoma	3.99e-05	0.000797	CcSEcCtD
Pazopanib—Dermatitis—Vincristine—sarcoma	3.98e-05	0.000797	CcSEcCtD
Pazopanib—Oedema peripheral—Epirubicin—sarcoma	3.98e-05	0.000796	CcSEcCtD
Pazopanib—Haematuria—Doxorubicin—sarcoma	3.97e-05	0.000794	CcSEcCtD
Pazopanib—Connective tissue disorder—Epirubicin—sarcoma	3.97e-05	0.000794	CcSEcCtD
Pazopanib—Urethral disorder—Epirubicin—sarcoma	3.96e-05	0.000792	CcSEcCtD
Pazopanib—Headache—Vincristine—sarcoma	3.96e-05	0.000792	CcSEcCtD
Pazopanib—Hepatobiliary disease—Doxorubicin—sarcoma	3.94e-05	0.000788	CcSEcCtD
Pazopanib—Epistaxis—Doxorubicin—sarcoma	3.93e-05	0.000786	CcSEcCtD
Pazopanib—Vomiting—Mitoxantrone—sarcoma	3.92e-05	0.000783	CcSEcCtD
Pazopanib—Rash—Mitoxantrone—sarcoma	3.88e-05	0.000777	CcSEcCtD
Pazopanib—Dermatitis—Mitoxantrone—sarcoma	3.88e-05	0.000776	CcSEcCtD
Pazopanib—Headache—Mitoxantrone—sarcoma	3.86e-05	0.000772	CcSEcCtD
Pazopanib—Bradycardia—Doxorubicin—sarcoma	3.81e-05	0.000761	CcSEcCtD
Pazopanib—ABCG2—bone marrow—sarcoma	3.79e-05	0.000713	CbGeAlD
Pazopanib—Eye disorder—Epirubicin—sarcoma	3.78e-05	0.000755	CcSEcCtD
Pazopanib—Haemoglobin—Doxorubicin—sarcoma	3.76e-05	0.000752	CcSEcCtD
Pazopanib—Nausea—Vincristine—sarcoma	3.76e-05	0.000751	CcSEcCtD
Pazopanib—Flushing—Epirubicin—sarcoma	3.75e-05	0.00075	CcSEcCtD
Pazopanib—Cardiac disorder—Epirubicin—sarcoma	3.75e-05	0.00075	CcSEcCtD
Pazopanib—Haemorrhage—Doxorubicin—sarcoma	3.74e-05	0.000748	CcSEcCtD
Pazopanib—Hypoaesthesia—Doxorubicin—sarcoma	3.72e-05	0.000744	CcSEcCtD
Pazopanib—Urinary tract disorder—Doxorubicin—sarcoma	3.69e-05	0.000739	CcSEcCtD
Pazopanib—Oedema peripheral—Doxorubicin—sarcoma	3.68e-05	0.000737	CcSEcCtD
Pazopanib—Asthenia—Etoposide—sarcoma	3.67e-05	0.000735	CcSEcCtD
Pazopanib—Connective tissue disorder—Doxorubicin—sarcoma	3.67e-05	0.000735	CcSEcCtD
Pazopanib—Angiopathy—Epirubicin—sarcoma	3.67e-05	0.000733	CcSEcCtD
Pazopanib—Urethral disorder—Doxorubicin—sarcoma	3.67e-05	0.000733	CcSEcCtD
Pazopanib—Nausea—Mitoxantrone—sarcoma	3.66e-05	0.000732	CcSEcCtD
Pazopanib—Mediastinal disorder—Epirubicin—sarcoma	3.64e-05	0.000729	CcSEcCtD
Pazopanib—Chills—Epirubicin—sarcoma	3.63e-05	0.000725	CcSEcCtD
Pazopanib—Pruritus—Etoposide—sarcoma	3.62e-05	0.000725	CcSEcCtD
Pazopanib—Alopecia—Epirubicin—sarcoma	3.57e-05	0.000714	CcSEcCtD
Pazopanib—Mental disorder—Epirubicin—sarcoma	3.54e-05	0.000708	CcSEcCtD
Pazopanib—Erythema—Epirubicin—sarcoma	3.52e-05	0.000704	CcSEcCtD
Pazopanib—Malnutrition—Epirubicin—sarcoma	3.52e-05	0.000704	CcSEcCtD
Pazopanib—Diarrhoea—Etoposide—sarcoma	3.5e-05	0.000701	CcSEcCtD
Pazopanib—Eye disorder—Doxorubicin—sarcoma	3.49e-05	0.000699	CcSEcCtD
Pazopanib—Flushing—Doxorubicin—sarcoma	3.47e-05	0.000694	CcSEcCtD
Pazopanib—Cardiac disorder—Doxorubicin—sarcoma	3.47e-05	0.000694	CcSEcCtD
Pazopanib—Flatulence—Epirubicin—sarcoma	3.47e-05	0.000693	CcSEcCtD
Pazopanib—Dysgeusia—Epirubicin—sarcoma	3.44e-05	0.000689	CcSEcCtD
Pazopanib—ABCB1—myometrium—sarcoma	3.4e-05	0.000639	CbGeAlD
Pazopanib—Angiopathy—Doxorubicin—sarcoma	3.39e-05	0.000679	CcSEcCtD
Pazopanib—Dizziness—Etoposide—sarcoma	3.39e-05	0.000678	CcSEcCtD
Pazopanib—Muscle spasms—Epirubicin—sarcoma	3.38e-05	0.000677	CcSEcCtD
Pazopanib—Mediastinal disorder—Doxorubicin—sarcoma	3.37e-05	0.000674	CcSEcCtD
Pazopanib—Chills—Doxorubicin—sarcoma	3.35e-05	0.000671	CcSEcCtD
Pazopanib—CYP2C8—testis—sarcoma	3.34e-05	0.000627	CbGeAlD
Pazopanib—Vision blurred—Epirubicin—sarcoma	3.32e-05	0.000663	CcSEcCtD
Pazopanib—Alopecia—Doxorubicin—sarcoma	3.3e-05	0.000661	CcSEcCtD
Pazopanib—Mental disorder—Doxorubicin—sarcoma	3.28e-05	0.000655	CcSEcCtD
Pazopanib—ABCB1—embryo—sarcoma	3.27e-05	0.000614	CbGeAlD
Pazopanib—Vomiting—Etoposide—sarcoma	3.26e-05	0.000651	CcSEcCtD
Pazopanib—Malnutrition—Doxorubicin—sarcoma	3.25e-05	0.000651	CcSEcCtD
Pazopanib—Erythema—Doxorubicin—sarcoma	3.25e-05	0.000651	CcSEcCtD
Pazopanib—Anaemia—Epirubicin—sarcoma	3.25e-05	0.00065	CcSEcCtD
Pazopanib—ABCG2—testis—sarcoma	3.24e-05	0.00061	CbGeAlD
Pazopanib—Rash—Etoposide—sarcoma	3.23e-05	0.000646	CcSEcCtD
Pazopanib—Dermatitis—Etoposide—sarcoma	3.23e-05	0.000645	CcSEcCtD
Pazopanib—Headache—Etoposide—sarcoma	3.21e-05	0.000642	CcSEcCtD
Pazopanib—Flatulence—Doxorubicin—sarcoma	3.21e-05	0.000642	CcSEcCtD
Pazopanib—Dysgeusia—Doxorubicin—sarcoma	3.19e-05	0.000638	CcSEcCtD
Pazopanib—Syncope—Epirubicin—sarcoma	3.15e-05	0.000631	CcSEcCtD
Pazopanib—CYP2C8—liver—sarcoma	3.15e-05	0.000593	CbGeAlD
Pazopanib—Leukopenia—Epirubicin—sarcoma	3.15e-05	0.00063	CcSEcCtD
Pazopanib—Muscle spasms—Doxorubicin—sarcoma	3.13e-05	0.000626	CcSEcCtD
Pazopanib—Loss of consciousness—Epirubicin—sarcoma	3.09e-05	0.000618	CcSEcCtD
Pazopanib—ABCB1—seminal vesicle—sarcoma	3.07e-05	0.000577	CbGeAlD
Pazopanib—Cough—Epirubicin—sarcoma	3.07e-05	0.000614	CcSEcCtD
Pazopanib—Vision blurred—Doxorubicin—sarcoma	3.07e-05	0.000614	CcSEcCtD
Pazopanib—ABCG2—liver—sarcoma	3.07e-05	0.000576	CbGeAlD
Pazopanib—Nausea—Etoposide—sarcoma	3.04e-05	0.000609	CcSEcCtD
Pazopanib—Hypertension—Epirubicin—sarcoma	3.04e-05	0.000608	CcSEcCtD
Pazopanib—Anaemia—Doxorubicin—sarcoma	3.01e-05	0.000602	CcSEcCtD
Pazopanib—Chest pain—Epirubicin—sarcoma	2.99e-05	0.000599	CcSEcCtD
Pazopanib—Myalgia—Epirubicin—sarcoma	2.99e-05	0.000599	CcSEcCtD
Pazopanib—Arthralgia—Epirubicin—sarcoma	2.99e-05	0.000599	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	2.97e-05	0.000595	CcSEcCtD
Pazopanib—CYP1A2—liver—sarcoma	2.95e-05	0.000555	CbGeAlD
Pazopanib—Dry mouth—Epirubicin—sarcoma	2.93e-05	0.000586	CcSEcCtD
Pazopanib—Syncope—Doxorubicin—sarcoma	2.92e-05	0.000584	CcSEcCtD
Pazopanib—ABCB1—hematopoietic system—sarcoma	2.92e-05	0.000548	CbGeAlD
Pazopanib—Leukopenia—Doxorubicin—sarcoma	2.91e-05	0.000583	CcSEcCtD
Pazopanib—Oedema—Epirubicin—sarcoma	2.87e-05	0.000574	CcSEcCtD
Pazopanib—Loss of consciousness—Doxorubicin—sarcoma	2.86e-05	0.000572	CcSEcCtD
Pazopanib—Infection—Epirubicin—sarcoma	2.85e-05	0.000571	CcSEcCtD
Pazopanib—Cough—Doxorubicin—sarcoma	2.84e-05	0.000568	CcSEcCtD
Pazopanib—Shock—Epirubicin—sarcoma	2.82e-05	0.000565	CcSEcCtD
Pazopanib—Nervous system disorder—Epirubicin—sarcoma	2.82e-05	0.000563	CcSEcCtD
Pazopanib—Thrombocytopenia—Epirubicin—sarcoma	2.81e-05	0.000562	CcSEcCtD
Pazopanib—Hypertension—Doxorubicin—sarcoma	2.81e-05	0.000562	CcSEcCtD
Pazopanib—Skin disorder—Epirubicin—sarcoma	2.79e-05	0.000558	CcSEcCtD
Pazopanib—Hyperhidrosis—Epirubicin—sarcoma	2.78e-05	0.000555	CcSEcCtD
Pazopanib—Chest pain—Doxorubicin—sarcoma	2.77e-05	0.000554	CcSEcCtD
Pazopanib—Myalgia—Doxorubicin—sarcoma	2.77e-05	0.000554	CcSEcCtD
Pazopanib—Arthralgia—Doxorubicin—sarcoma	2.77e-05	0.000554	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	2.75e-05	0.000551	CcSEcCtD
Pazopanib—Anorexia—Epirubicin—sarcoma	2.74e-05	0.000547	CcSEcCtD
Pazopanib—Dry mouth—Doxorubicin—sarcoma	2.71e-05	0.000542	CcSEcCtD
Pazopanib—Oedema—Doxorubicin—sarcoma	2.66e-05	0.000531	CcSEcCtD
Pazopanib—Infection—Doxorubicin—sarcoma	2.64e-05	0.000528	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Epirubicin—sarcoma	2.62e-05	0.000523	CcSEcCtD
Pazopanib—Shock—Doxorubicin—sarcoma	2.61e-05	0.000523	CcSEcCtD
Pazopanib—Nervous system disorder—Doxorubicin—sarcoma	2.61e-05	0.000521	CcSEcCtD
Pazopanib—Thrombocytopenia—Doxorubicin—sarcoma	2.6e-05	0.00052	CcSEcCtD
Pazopanib—Insomnia—Epirubicin—sarcoma	2.6e-05	0.000519	CcSEcCtD
Pazopanib—Skin disorder—Doxorubicin—sarcoma	2.58e-05	0.000516	CcSEcCtD
Pazopanib—Paraesthesia—Epirubicin—sarcoma	2.58e-05	0.000516	CcSEcCtD
Pazopanib—Hyperhidrosis—Doxorubicin—sarcoma	2.57e-05	0.000514	CcSEcCtD
Pazopanib—Dyspnoea—Epirubicin—sarcoma	2.56e-05	0.000512	CcSEcCtD
Pazopanib—Somnolence—Epirubicin—sarcoma	2.55e-05	0.000511	CcSEcCtD
Pazopanib—Anorexia—Doxorubicin—sarcoma	2.53e-05	0.000507	CcSEcCtD
Pazopanib—Dyspepsia—Epirubicin—sarcoma	2.53e-05	0.000506	CcSEcCtD
Pazopanib—Decreased appetite—Epirubicin—sarcoma	2.5e-05	0.000499	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Epirubicin—sarcoma	2.48e-05	0.000496	CcSEcCtD
Pazopanib—Fatigue—Epirubicin—sarcoma	2.48e-05	0.000495	CcSEcCtD
Pazopanib—Pain—Epirubicin—sarcoma	2.46e-05	0.000491	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Doxorubicin—sarcoma	2.42e-05	0.000484	CcSEcCtD
Pazopanib—Insomnia—Doxorubicin—sarcoma	2.4e-05	0.000481	CcSEcCtD
Pazopanib—Paraesthesia—Doxorubicin—sarcoma	2.39e-05	0.000477	CcSEcCtD
Pazopanib—Dyspnoea—Doxorubicin—sarcoma	2.37e-05	0.000474	CcSEcCtD
Pazopanib—Somnolence—Doxorubicin—sarcoma	2.36e-05	0.000472	CcSEcCtD
Pazopanib—ABCG2—lymph node—sarcoma	2.35e-05	0.000442	CbGeAlD
Pazopanib—Gastrointestinal pain—Epirubicin—sarcoma	2.35e-05	0.00047	CcSEcCtD
Pazopanib—Dyspepsia—Doxorubicin—sarcoma	2.34e-05	0.000468	CcSEcCtD
Pazopanib—Decreased appetite—Doxorubicin—sarcoma	2.31e-05	0.000462	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Doxorubicin—sarcoma	2.29e-05	0.000459	CcSEcCtD
Pazopanib—Fatigue—Doxorubicin—sarcoma	2.29e-05	0.000458	CcSEcCtD
Pazopanib—Pain—Doxorubicin—sarcoma	2.27e-05	0.000454	CcSEcCtD
Pazopanib—Abdominal pain—Epirubicin—sarcoma	2.27e-05	0.000454	CcSEcCtD
Pazopanib—CYP2D6—testis—sarcoma	2.22e-05	0.000418	CbGeAlD
Pazopanib—ABCB1—uterus—sarcoma	2.2e-05	0.000414	CbGeAlD
Pazopanib—Gastrointestinal pain—Doxorubicin—sarcoma	2.17e-05	0.000435	CcSEcCtD
Pazopanib—CYP3A4—liver—sarcoma	2.14e-05	0.000401	CbGeAlD
Pazopanib—CYP2D6—liver—sarcoma	2.1e-05	0.000395	CbGeAlD
Pazopanib—Abdominal pain—Doxorubicin—sarcoma	2.1e-05	0.00042	CcSEcCtD
Pazopanib—Asthenia—Epirubicin—sarcoma	2.06e-05	0.000412	CcSEcCtD
Pazopanib—ABCB1—lymphoid tissue—sarcoma	2.05e-05	0.000386	CbGeAlD
Pazopanib—Pruritus—Epirubicin—sarcoma	2.03e-05	0.000406	CcSEcCtD
Pazopanib—Diarrhoea—Epirubicin—sarcoma	1.96e-05	0.000393	CcSEcCtD
Pazopanib—Asthenia—Doxorubicin—sarcoma	1.91e-05	0.000381	CcSEcCtD
Pazopanib—Dizziness—Epirubicin—sarcoma	1.9e-05	0.00038	CcSEcCtD
Pazopanib—Pruritus—Doxorubicin—sarcoma	1.88e-05	0.000376	CcSEcCtD
Pazopanib—ABCB1—bone marrow—sarcoma	1.87e-05	0.000352	CbGeAlD
Pazopanib—Vomiting—Epirubicin—sarcoma	1.83e-05	0.000365	CcSEcCtD
Pazopanib—Diarrhoea—Doxorubicin—sarcoma	1.82e-05	0.000364	CcSEcCtD
Pazopanib—Rash—Epirubicin—sarcoma	1.81e-05	0.000362	CcSEcCtD
Pazopanib—Dermatitis—Epirubicin—sarcoma	1.81e-05	0.000362	CcSEcCtD
Pazopanib—Headache—Epirubicin—sarcoma	1.8e-05	0.00036	CcSEcCtD
Pazopanib—Dizziness—Doxorubicin—sarcoma	1.76e-05	0.000351	CcSEcCtD
Pazopanib—Nausea—Epirubicin—sarcoma	1.71e-05	0.000341	CcSEcCtD
Pazopanib—Vomiting—Doxorubicin—sarcoma	1.69e-05	0.000338	CcSEcCtD
Pazopanib—Rash—Doxorubicin—sarcoma	1.67e-05	0.000335	CcSEcCtD
Pazopanib—Dermatitis—Doxorubicin—sarcoma	1.67e-05	0.000335	CcSEcCtD
Pazopanib—Headache—Doxorubicin—sarcoma	1.66e-05	0.000333	CcSEcCtD
Pazopanib—ABCB1—testis—sarcoma	1.6e-05	0.000301	CbGeAlD
Pazopanib—Nausea—Doxorubicin—sarcoma	1.58e-05	0.000316	CcSEcCtD
Pazopanib—ABCB1—liver—sarcoma	1.51e-05	0.000284	CbGeAlD
Pazopanib—ABCB1—lymph node—sarcoma	1.16e-05	0.000218	CbGeAlD
Pazopanib—PDGFRA—Disease—CTNNB1—sarcoma	1.6e-06	1.98e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—NRAS—sarcoma	1.59e-06	1.97e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—HRAS—sarcoma	1.59e-06	1.97e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—TP53—sarcoma	1.59e-06	1.96e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PLCG1—sarcoma	1.59e-06	1.96e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—SRC—sarcoma	1.58e-06	1.96e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—IL2—sarcoma	1.58e-06	1.96e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—CCND1—sarcoma	1.58e-06	1.96e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—IL2—sarcoma	1.58e-06	1.95e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—KDR—sarcoma	1.58e-06	1.95e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—JUN—sarcoma	1.58e-06	1.95e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CREB1—sarcoma	1.57e-06	1.95e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—JUN—sarcoma	1.57e-06	1.94e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—SRC—sarcoma	1.57e-06	1.94e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CREB1—sarcoma	1.57e-06	1.94e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—CTNNB1—sarcoma	1.57e-06	1.94e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—SRC—sarcoma	1.57e-06	1.94e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—FOXO1—sarcoma	1.57e-06	1.93e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PDGFRB—sarcoma	1.56e-06	1.93e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—CTNNB1—sarcoma	1.56e-06	1.93e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—KRAS—sarcoma	1.56e-06	1.92e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—SRC—sarcoma	1.56e-06	1.92e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—KRAS—sarcoma	1.55e-06	1.91e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—VEGFA—sarcoma	1.54e-06	1.91e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—CCND1—sarcoma	1.54e-06	1.91e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—JUN—sarcoma	1.54e-06	1.9e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—JUN—sarcoma	1.54e-06	1.9e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PDGFRA—sarcoma	1.54e-06	1.9e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ENO2—sarcoma	1.54e-06	1.9e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—CTNNB1—sarcoma	1.53e-06	1.89e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—SRC—sarcoma	1.53e-06	1.89e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—CTNNB1—sarcoma	1.53e-06	1.89e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—TP53—sarcoma	1.53e-06	1.89e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—HBA1—sarcoma	1.53e-06	1.88e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—NRAS—sarcoma	1.52e-06	1.88e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—HRAS—sarcoma	1.52e-06	1.88e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—NRAS—sarcoma	1.51e-06	1.87e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—IL2—sarcoma	1.51e-06	1.86e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—NRAS—sarcoma	1.51e-06	1.86e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—NRAS—sarcoma	1.5e-06	1.85e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—KIT—sarcoma	1.49e-06	1.84e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—EGFR—sarcoma	1.48e-06	1.83e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—CCND1—sarcoma	1.47e-06	1.82e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—NRAS—sarcoma	1.47e-06	1.82e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—JUN—sarcoma	1.47e-06	1.81e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—HRAS—sarcoma	1.46e-06	1.8e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—CTNNB1—sarcoma	1.46e-06	1.8e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—KIT—sarcoma	1.46e-06	1.8e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—MDM2—sarcoma	1.45e-06	1.8e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—EGFR—sarcoma	1.45e-06	1.79e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—SRC—sarcoma	1.45e-06	1.79e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—SRC—sarcoma	1.45e-06	1.79e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—CTNNB1—sarcoma	1.44e-06	1.78e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—HRAS—sarcoma	1.43e-06	1.77e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—MYC—sarcoma	1.42e-06	1.75e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—SRC—sarcoma	1.42e-06	1.75e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CREB1—sarcoma	1.42e-06	1.75e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—SRC—sarcoma	1.41e-06	1.74e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MDM2—sarcoma	1.4e-06	1.73e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—KRAS—sarcoma	1.4e-06	1.72e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—NRAS—sarcoma	1.4e-06	1.72e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—MYC—sarcoma	1.39e-06	1.72e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—NRAS—sarcoma	1.39e-06	1.72e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—EGFR—sarcoma	1.39e-06	1.72e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CREB1—sarcoma	1.39e-06	1.71e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—SRC—sarcoma	1.38e-06	1.71e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PLCG1—sarcoma	1.38e-06	1.71e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—SRC—sarcoma	1.38e-06	1.71e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—VEGFA—sarcoma	1.38e-06	1.7e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—EGFR—sarcoma	1.38e-06	1.7e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—EGFR—sarcoma	1.37e-06	1.7e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MDM2—sarcoma	1.37e-06	1.7e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—KRAS—sarcoma	1.37e-06	1.69e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—MYC—sarcoma	1.37e-06	1.69e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—HRAS—sarcoma	1.37e-06	1.69e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—EGFR—sarcoma	1.36e-06	1.69e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—NRAS—sarcoma	1.36e-06	1.68e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—NRAS—sarcoma	1.36e-06	1.68e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—VEGFA—sarcoma	1.34e-06	1.66e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—MDM2—sarcoma	1.34e-06	1.66e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—EGFR—sarcoma	1.34e-06	1.66e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—NRAS—sarcoma	1.33e-06	1.64e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—NRAS—sarcoma	1.33e-06	1.64e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—HRAS—sarcoma	1.32e-06	1.64e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—SRC—sarcoma	1.32e-06	1.63e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—HRAS—sarcoma	1.31e-06	1.62e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—KRAS—sarcoma	1.31e-06	1.62e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—SRC—sarcoma	1.3e-06	1.61e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MDM2—sarcoma	1.3e-06	1.61e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PLCG1—sarcoma	1.3e-06	1.61e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—KRAS—sarcoma	1.3e-06	1.61e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ENO2—sarcoma	1.3e-06	1.61e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—MYC—sarcoma	1.3e-06	1.61e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MDM2—sarcoma	1.3e-06	1.61e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL2—sarcoma	1.3e-06	1.6e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—KRAS—sarcoma	1.3e-06	1.6e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—MYC—sarcoma	1.3e-06	1.6e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—KDR—sarcoma	1.3e-06	1.6e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—HBA1—sarcoma	1.29e-06	1.6e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—KRAS—sarcoma	1.29e-06	1.59e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—VEGFA—sarcoma	1.28e-06	1.58e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—EGFR—sarcoma	1.27e-06	1.57e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—MYC—sarcoma	1.27e-06	1.57e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—EGFR—sarcoma	1.27e-06	1.57e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—NRAS—sarcoma	1.27e-06	1.57e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—KRAS—sarcoma	1.27e-06	1.56e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—JUN—sarcoma	1.26e-06	1.56e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—NRAS—sarcoma	1.25e-06	1.55e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—CTNNB1—sarcoma	1.25e-06	1.55e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IL2—sarcoma	1.25e-06	1.54e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—EGFR—sarcoma	1.24e-06	1.53e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—EGFR—sarcoma	1.24e-06	1.53e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—MYC—sarcoma	1.24e-06	1.53e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IL2—sarcoma	1.23e-06	1.52e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CCND1—sarcoma	1.22e-06	1.5e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—JUN—sarcoma	1.22e-06	1.5e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—EGFR—sarcoma	1.21e-06	1.5e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—EGFR—sarcoma	1.21e-06	1.49e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CTNNB1—sarcoma	1.21e-06	1.49e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—KRAS—sarcoma	1.2e-06	1.48e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—KRAS—sarcoma	1.2e-06	1.48e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CCND1—sarcoma	1.2e-06	1.48e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—JUN—sarcoma	1.19e-06	1.47e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—KIT—sarcoma	1.19e-06	1.47e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—HRAS—sarcoma	1.19e-06	1.47e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CTNNB1—sarcoma	1.18e-06	1.46e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—MYC—sarcoma	1.18e-06	1.46e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—KRAS—sarcoma	1.17e-06	1.45e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MDM2—sarcoma	1.17e-06	1.45e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—KRAS—sarcoma	1.17e-06	1.44e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—MYC—sarcoma	1.17e-06	1.44e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—TP53—sarcoma	1.17e-06	1.44e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—HRAS—sarcoma	1.17e-06	1.44e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IL2—sarcoma	1.16e-06	1.44e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IL2—sarcoma	1.16e-06	1.43e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—CTNNB1—sarcoma	1.16e-06	1.43e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—EGFR—sarcoma	1.15e-06	1.43e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MDM2—sarcoma	1.15e-06	1.42e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—KRAS—sarcoma	1.14e-06	1.41e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—KRAS—sarcoma	1.14e-06	1.41e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—EGFR—sarcoma	1.14e-06	1.41e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CREB1—sarcoma	1.14e-06	1.4e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CCND1—sarcoma	1.13e-06	1.4e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—SRC—sarcoma	1.13e-06	1.4e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—JUN—sarcoma	1.13e-06	1.4e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CCND1—sarcoma	1.13e-06	1.4e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—JUN—sarcoma	1.13e-06	1.4e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CTNNB1—sarcoma	1.12e-06	1.39e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CTNNB1—sarcoma	1.12e-06	1.38e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—HRAS—sarcoma	1.12e-06	1.38e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—HRAS—sarcoma	1.11e-06	1.37e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PLCG1—sarcoma	1.1e-06	1.36e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—HRAS—sarcoma	1.1e-06	1.36e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—HRAS—sarcoma	1.1e-06	1.35e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—KRAS—sarcoma	1.09e-06	1.35e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—NRAS—sarcoma	1.09e-06	1.35e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—SRC—sarcoma	1.09e-06	1.35e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—KRAS—sarcoma	1.08e-06	1.33e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—HRAS—sarcoma	1.08e-06	1.33e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—SRC—sarcoma	1.07e-06	1.32e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—VEGFA—sarcoma	1.06e-06	1.31e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—NRAS—sarcoma	1.05e-06	1.3e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IL2—sarcoma	1.05e-06	1.29e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—SRC—sarcoma	1.05e-06	1.29e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—VEGFA—sarcoma	1.04e-06	1.29e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—TP53—sarcoma	1.04e-06	1.29e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—NRAS—sarcoma	1.03e-06	1.27e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IL2—sarcoma	1.02e-06	1.27e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—HRAS—sarcoma	1.02e-06	1.26e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CCND1—sarcoma	1.02e-06	1.26e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—HRAS—sarcoma	1.02e-06	1.26e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—JUN—sarcoma	1.02e-06	1.26e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—TP53—sarcoma	1.02e-06	1.25e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—SRC—sarcoma	1.02e-06	1.25e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—SRC—sarcoma	1.01e-06	1.25e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CTNNB1—sarcoma	1.01e-06	1.25e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—NRAS—sarcoma	1.01e-06	1.24e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ENO2—sarcoma	1e-06	1.24e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CCND1—sarcoma	9.98e-07	1.23e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—HBA1—sarcoma	9.97e-07	1.23e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—HRAS—sarcoma	9.97e-07	1.23e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—JUN—sarcoma	9.96e-07	1.23e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—HRAS—sarcoma	9.94e-07	1.23e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—EGFR—sarcoma	9.93e-07	1.23e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—VEGFA—sarcoma	9.89e-07	1.22e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CTNNB1—sarcoma	9.89e-07	1.22e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—VEGFA—sarcoma	9.87e-07	1.22e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—NRAS—sarcoma	9.77e-07	1.21e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MYC—sarcoma	9.77e-07	1.21e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—NRAS—sarcoma	9.75e-07	1.2e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—HRAS—sarcoma	9.73e-07	1.2e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—HRAS—sarcoma	9.72e-07	1.2e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TP53—sarcoma	9.69e-07	1.2e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MYC—sarcoma	9.59e-07	1.18e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—EGFR—sarcoma	9.55e-07	1.18e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MDM2—sarcoma	9.4e-07	1.16e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—EGFR—sarcoma	9.38e-07	1.16e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—KRAS—sarcoma	9.38e-07	1.16e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—MYC—sarcoma	9.37e-07	1.16e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—HRAS—sarcoma	9.27e-07	1.14e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—HRAS—sarcoma	9.17e-07	1.13e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—EGFR—sarcoma	9.17e-07	1.13e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—SRC—sarcoma	9.13e-07	1.13e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MYC—sarcoma	9.1e-07	1.12e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MYC—sarcoma	9.08e-07	1.12e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—KRAS—sarcoma	9.02e-07	1.11e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—SRC—sarcoma	8.94e-07	1.1e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—EGFR—sarcoma	8.9e-07	1.1e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—VEGFA—sarcoma	8.89e-07	1.1e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—EGFR—sarcoma	8.88e-07	1.1e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—KRAS—sarcoma	8.86e-07	1.09e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—NRAS—sarcoma	8.78e-07	1.08e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—VEGFA—sarcoma	8.7e-07	1.08e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—KRAS—sarcoma	8.66e-07	1.07e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—NRAS—sarcoma	8.6e-07	1.06e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PLCG1—sarcoma	8.52e-07	1.05e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—KRAS—sarcoma	8.41e-07	1.04e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL2—sarcoma	8.4e-07	1.04e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—KRAS—sarcoma	8.39e-07	1.04e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CCND1—sarcoma	8.18e-07	1.01e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MYC—sarcoma	8.18e-07	1.01e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—JUN—sarcoma	8.17e-07	1.01e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CTNNB1—sarcoma	8.1e-07	1e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TP53—sarcoma	8.02e-07	9.91e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MYC—sarcoma	8.01e-07	9.89e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—EGFR—sarcoma	8e-07	9.88e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—HRAS—sarcoma	7.97e-07	9.85e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TP53—sarcoma	7.88e-07	9.73e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—EGFR—sarcoma	7.83e-07	9.68e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—HRAS—sarcoma	7.67e-07	9.48e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—KRAS—sarcoma	7.56e-07	9.34e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—HRAS—sarcoma	7.53e-07	9.31e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TP53—sarcoma	7.48e-07	9.24e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TP53—sarcoma	7.46e-07	9.21e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—KRAS—sarcoma	7.4e-07	9.14e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—HRAS—sarcoma	7.36e-07	9.1e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—SRC—sarcoma	7.33e-07	9.05e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—HRAS—sarcoma	7.15e-07	8.83e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—VEGFA—sarcoma	7.13e-07	8.81e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—HRAS—sarcoma	7.13e-07	8.81e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NRAS—sarcoma	7.05e-07	8.71e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TP53—sarcoma	6.72e-07	8.3e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TP53—sarcoma	6.58e-07	8.12e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MYC—sarcoma	6.56e-07	8.11e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—HRAS—sarcoma	6.42e-07	7.94e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—EGFR—sarcoma	6.42e-07	7.93e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—HRAS—sarcoma	6.29e-07	7.77e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—KRAS—sarcoma	6.07e-07	7.49e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TP53—sarcoma	5.39e-07	6.66e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—HRAS—sarcoma	5.16e-07	6.37e-06	CbGpPWpGaD
